Latest Fairmount Funds Management LLC Stock Portfolio
Fairmount Funds Management LLC Performance:
2025 Q3: 26.87%YTD: 13.31%2024: 16.09%
Performance for 2025 Q3 is 26.87%, and YTD is 13.31%, and 2024 is 16.09%.
About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $1.1 Billions as of 30 Sep, 2025.
The top stock holdings of Fairmount Funds Management LLC are , COGT, AXSM. The fund has invested 11.7% of it's portfolio in DIANTHUS THERAPEUTICS INC and 11.6% of portfolio in COGENT BIOSCIENCES INC.
The fund managers got completely rid off CYTOMX THERAPEUTICS INC (CTMX) stocks. Fairmount Funds Management LLC opened new stock positions in ABIVAX SA. The fund showed a lot of confidence in some stocks as they added substantially to COGENT BIOSCIENCES INC (COGT) and DIANTHUS THERAPEUTICS INC.
The top stock holdings of Fairmount Funds Management LLC are , COGT, AXSM. The fund has invested 11.7% of it's portfolio in DIANTHUS THERAPEUTICS INC and 11.6% of portfolio in COGENT BIOSCIENCES INC.
The fund managers got completely rid off CYTOMX THERAPEUTICS INC (CTMX) stocks. Fairmount Funds Management LLC opened new stock positions in ABIVAX SA. The fund showed a lot of confidence in some stocks as they added substantially to COGENT BIOSCIENCES INC (COGT) and DIANTHUS THERAPEUTICS INC.
Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Fairmount Funds Management LLC made a return of 26.87% in the last quarter. In trailing 12 months, it's portfolio return was -5.25%.
New Buys
| Ticker | $ Bought |
|---|---|
| abivax sa | 60,570,500 |
New stocks bought by Fairmount Funds Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| cogent biosciences inc | 44.62 |
| dianthus therapeutics inc | 22.16 |
| oruka therapeutics inc | 9.89 |
Additions to existing portfolio by Fairmount Funds Management LLC
Reductions
Sold off
| Ticker | $ Sold |
|---|---|
| cytomx therapeutics inc | -8,845,240 |
Fairmount Funds Management LLC got rid off the above stocks
Sector Distribution
Fairmount Funds Management LLC has about 50.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 50.8 |
| Others | 49.2 |
Market Cap. Distribution
Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 49.2 |
| SMALL-CAP | 32.8 |
| MID-CAP | 14.6 |
| NANO-CAP | 3.4 |
Stocks belong to which Index?
About 43.9% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 56.1 |
| RUSSELL 2000 | 43.9 |
Fairmount Funds Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Fairmount Funds Management LLC
Fairmount Funds Management LLC has 17 stocks in it's portfolio. About 77.9% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for Fairmount Funds Management LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 6.06 | 4,018,100 | 67,343,400 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 2.33 | 3,554,130 | 25,874,100 | unchanged | 0.00 | ||
| AVTE | jade biosciences inc | 2.50 | 3,220,370 | 27,791,800 | unchanged | 0.00 | ||
| AXSM | axsome therapeutics inc | 8.91 | 815,176 | 99,003,100 | unchanged | 0.00 | ||
| COGT | cogent biosciences inc | 11.63 | 9,003,420 | 129,289,000 | added | 44.62 | ||
| CTMX | cytomx therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IKT | inhibikase therapeutics inc | 0.89 | 6,125,000 | 9,922,500 | unchanged | 0.00 | ||
| NUVL | nuvalent inc | 5.66 | 727,563 | 62,919,600 | unchanged | 0.00 | ||
| SRRK | scholar rock hldg corp | 6.11 | 1,824,030 | 67,926,900 | unchanged | 0.00 | ||
| VRDN | viridian therapeutics inc | 6.72 | 3,459,910 | 74,664,900 | unchanged | 0.00 | ||
| dianthus therapeutics inc | 11.71 | 3,307,190 | 130,138,000 | added | 22.16 | |||
| apogee therapeutics inc | 7.32 | 2,048,650 | 81,392,700 | unchanged | 0.00 | |||
| enliven therapeutics inc | 6.84 | 3,711,440 | 75,973,300 | unchanged | 0.00 | |||
| oruka therapeutics inc | 6.41 | 3,705,260 | 71,252,200 | added | 9.89 | |||
| kiniksa pharmaceuticals intl | 6.19 | 1,772,840 | 68,839,300 | unchanged | 0.00 | |||
| abivax sa | 5.45 | 713,434 | 60,570,500 | new | ||||
| zenas biopharma inc | 3.78 | 1,892,810 | 42,020,300 | unchanged | 0.00 | |||
| crescent biopharma inc. | 1.49 | 1,387,870 | 16,501,700 | unchanged | 0.00 | |||